Prostate Cancer Recurrence Linked to Surgeon's Skill

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 5
Volume 15
Issue 5

The 5-year incidence of biochemical recurrence (BCR) of prostate cancer decreases with increased experience of the surgeon performing the prostatectomy, Fernando Bianco, MD, reported at the 2006 Prostate Cancer Symposium (abstract 272).

SAN FRANCISCO—The 5-year incidence of biochemical recurrence (BCR) of prostate cancer decreases with increased experience of the surgeon performing the prostatectomy, Fernando Bianco, MD, reported at the 2006 Prostate Cancer Symposium (abstract 272).

Dr. Bianco, a urologic oncology fellow at Memorial Sloan-Kettering Cancer Center, and his colleagues analyzed the incidence of BCR in 7,849 men who had a radical prostatectomy performed by one of 74 surgeons at four institutions between 1987 and 2003. A meta-analysis that controlled for PSA, Gleason score, positive margin, stage, and surgical expertise was performed, using the I2 statistic to determine the proportion of the variation that was due to true differences rather than chance alone.

The 5-year probability of freedom from BCR was 79% and 88% if the surgeon had previously performed 10 or 250 prostatectomies, respectively, he said.

There was also significant heterogeneity in BCR rates between individual surgeons (P < .0005), independent of experience. The I2 analysis indicated that 54% of the difference in BCR rates between high-volume surgeons (at least 40 lifetime surgeries) was due to differences in surgical technique and approach.

"While the rate of recurrence is largely determined by tumor stage, grade, and PSA level, surgical technique and decision-making in the operating room also play a role in patient outcome," he said. He called the existence of heterogeneity between surgeons "undesirable," and recommended that prospective randomized trials be designed to account for these effects "either by equality in randomization or showing no significant heterogeneity among providers."

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content